Ascelia Pharma AB stock analysis
Ascelia Pharma AB (7ZA) Stock Price & Analysis
7ZA Stock Chart & Stats
- Day’s Range
- EUR 0.04 - EUR 0.04
- 52-Week Range
- EUR 0.00 - EUR 0.37
- Previous Close
- EUR 0.04
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 6.97M
- Enterprise Value
- EUR 78.24M
- Total Cash (Recent Filing)
- EUR 27.80M
- Total Debt (Recent Filing)
- EUR 285.00K
- Price to Earnings (P/E)
- ―
- Beta
- 55.11
- Next Earnings
- Feb 11, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Very low debt reduces refinancing pressure and interest burden while preserving financial flexibility. Compared with a highly leveraged biotech, Ascelia has less obligation to divert future capital toward debt service, leaving more capacity for clinical development and regulatory work if financing remains available.
Narrowing Losses
The substantial reduction in operating losses indicates that spending or operational efficiency has improved from the 2022–2023 peak. Although profitability remains distant, a lower burn rate can extend financial runway and make future funding requirements more manageable as the company advances its lead program.
Focused Oncology Imaging Pipeline
A focused lead product gives Ascelia a clear development and commercialization objective rather than a broad, unfocused pipeline. Orviglance targets liver-metastasis imaging and could address a defined clinical need, creating a pathway to specialized product revenue if approval and adoption are achieved.
Bears Say
No Established Revenue
Ascelia has not yet demonstrated commercial demand or revenue scale, leaving its business model dependent on successful development and approval of Orviglance. Until product sales begin, fixed research and operating costs cannot be absorbed by recurring revenue, keeping execution risk elevated.
Persistent Cash Burn
Consistently negative operating and free cash flow means the company is consuming cash rather than internally funding its programs. This creates continuing dependence on external financing before commercialization, potentially limiting strategic flexibility and exposing development plans to future funding availability.
Eroded Equity Base
The sharp decline in equity reflects the cumulative effect of sustained losses and balance-sheet consumption. A smaller capital base provides less financial resilience for prolonged development timelines, while strongly negative returns show that invested capital is not yet generating economic returns for shareholders.
Ascelia Pharma AB News
7ZA FAQ
What was Ascelia Pharma AB’s price range in the past 12 months?
What is Ascelia Pharma AB’s market cap?
When is Ascelia Pharma AB’s upcoming earnings report date?
How were Ascelia Pharma AB’s earnings last quarter?
Is Ascelia Pharma AB overvalued?
Does Ascelia Pharma AB pay dividends?
What is Ascelia Pharma AB’s EPS estimate?
How many shares outstanding does Ascelia Pharma AB have?
What happened to Ascelia Pharma AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ascelia Pharma AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ascelia Pharma AB
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Magnus O. Corfitzen
- Employees
- 10
- Website
- www.ascelia.com
- Address
- Hyllie Boulevard 34, Malmö, SN, 215 32, SE
Ascelia Pharma AB (7ZA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 12 |
| Technical Analysis | 3 | 5 | 1 |
| Moving Averages | 1 | 0 | 11 |










